Touchlight welcomes Anjum Ahmad as Chief Financial Officer

Anjum Ahmad brings extensive insight in the UK’s life sciences sector having been the longstanding Group Finance Director of Touchstone Innovations Plc (formerly Imperial Innovations) – the AIM listed venture capital investor in early stage science.

In his former role at Touchstone he was one of the four-person senior executive team, presenting over £200m of investment opportunities in the therapeutics/biotech field to the Luxembourg Board, managing the corporate finance activity for an equity raise of £250m, responsible for the finance/treasury tax operations, conducting portfolio company asset valuations, and presenting the interim/year end results alongside their CEO. He was also responsible for their I.T. and H.R. functions.

Prior to Imperial Innovations he held finance positions within a tech start-up and GSK.

- ENDS -

About Touchlight

Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.

For more information please contact: